Use of depot GnRH antagonist (Degarelix) in the treatment of endometriomas (ovarian endometriosis) before IVF: A controlled trial

Not yet translated Not yet translated
Authors
Category Primary study
JournalFertility and Sterility
Year 2015
OBJECTIVE: Endometriosis is a chronic condition affecting around 10% of women in reproductive age, and after surgery it recur in about 50% of cases. It is recognized that surgical treatment of ovarian endometriomas affects ovarian reserve. For this reason in case of ovarian endometriomas we tried a medical approach instead of the surgery using a long acting GnRH antagonist. The aim of the study was to evaluate the role Degarelix (Firmagon) in the treatment of women with ovarian endometriosis (endometriomas) before undergo IVF in order to reduce cyst volume and improve IVF outcome avoiding surgery. DESIGN: This randomized controlled study was conducted from the January 2014 to April 2015 on 58 women with ovarian endometriomas. MATERIALS AND METHODS: All patients were affected by ovarian endometriosis with endometriomas larger than 3.5cm in mean diameter. All patients din not undergo surgery for endometriosis and they underwent a subsequent IVF cycle in the next 4-8 months. The mean age of women was 35.1 + 2.0 (range 25/39). The women were assigned to the study group or to the control group by a computer generated sequence. The 31 women of the study group were treated with a single injection of Degarelix (Firmagon 120mg) subcutaneously, The 27 women of the control group were treated for 6 months with Leuprolide 3.75 mg/month alone. The women of the two groups were followed up during the treatment and after the treatment for IVF cycles. All patients underwent IVF within 3 months from the end of treatment. All patients were treated for the controlled ovarian hyperstimulation with the same protocol, a standard flexible GnRH antagonist protocol with recombinant FSH (Gonal-F) plus Cetrorelix (Cetrotide). Primary outcomes were time of endometriomas disappearance and IVF outcome. RESULTS: The two groups of patients did not show statistically significant differences for epidemiological data. The time of endometriomas disappearance was shorter in the group treated with Degarelix than in the control group (2.4+0.9months vs 4.1+1.2months, P<0.01). The pregnancy rate for IVF in the women treated with Degarelix was significantly higher than in the control group (45.1% vs 18.5%, P=0.049). The implantation rate was 19.1 in Degarelix group versus 7.5 in controls (P=0.0416). The number of mature oocyte collected was 8.6+3.4 in Degarelix group and 6.1+3.6 in controls (P=0.0087). The number of embryo obtained was 4.7+1.2 in Degarelix group and 3.2+1.1 in controls (P<0.0001). CONCLUSIONS: Even though our data need to be validated in larger group of patients, Degarelix treatment seems to be a promising tool in patients with ovarian endometriosis, especially to avoid surgery in order to preserve ovarian reserve, improving IVF outcome.
Epistemonikos ID: ddfec6f8b5648a389d83fecafee9a0eac4bec9db
First added on: Feb 07, 2025